US › Healthcare

HUTCHMED DRC (HCM)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$11.57+0.17%
Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue
$135.4M
Revenue YoY
-16.5%
Net profit
$977,500
Profit YoY
-83.6%
EPS
$0.00
EPS estimate
$0.00
Net margin
0.7%

Key statistics

Market cap
$2.01B
P/E
115.5
Forward P/E
12.6
P/B
1.53
Book value
$7.25
EPS (TTM)
$0.10
52-week high
$18.30
52-week low
$9.77
50-day MA
$11.04
200-day MA
$13.57
Beta
0.44

Analyst view

Analysts rate HUTCHMED DRC a buy (11 buy, 3 hold, 0 sell out of 14) with an average price target of $21.77.

Shareholding

Insiders
0.01%
Institutions
2.57%

Largest institutional holders

FundStake
Schroder Investment Management Group0.85%
Allianz Asset Management AG0.48%
State Street Corp0.18%
AIA Group Ltd0.17%
M&G PLC0.15%
Amundi0.13%
Renaissance Technologies Corp0.08%
BNP Paribas Arbitrage, SA0.06%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for HUTCHMED DRC — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.